You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.
The opening of adult-use sales in New Jersey, which could happen as early as May, is one of the big catalysts for 2022 that we have previously discussed. In addition to injecting revenue into the almost exclusively publicly-traded companies operating in the state, we think that this could capture media attention and potentially attract investors to the sector.
This week, we learned that New York, which had been expected to launch in 2023, may also launch later this year, which adds to the positive dynamic we envisioned. While some may be disappointed with how the state intends to award initial retail licenses to equity-entrepreneurs with a prior cannabis-related criminal offense who also have a background owning and operating a small business while not allowing existing medical operators to open adult-use stores simultaneously, we believe that this move could make the state’s launch extremely robust.
In many states and in Canada, the limited number of stores at the launch of adult-use programs stunted the initial growth in sales. Without adequate distribution, markets were slow to develop. On the Green Thumb Industries call recently, CEO Ben Kovler chided Illinois for its delay in issuing the social-equity licenses that have been caught up in litigation. The state’s adult-use program, now in its third year, has only 110 stores open, or one per each 115K residents. While we are excited about the pending launch in New Jersey, there will be only a limited number of dispensaries open initially, perhaps 15, which suggests a slow start.
If New York were to go live with only the existing 10 medical operators opening their allotted three stores, there would be only 30 stores in the entire state. The move to enable a sub-set of equity-entrepreneurs to have a head start will allow for a lot more stores to be open in the early days. Outdoor growers under the hemp program will supply these stores to some extent, but so will the existing operators. Thus, the current medical-cannabis operators may be temporarily disadvantaged by having to delay their store openings, but they will benefit immensely from being able to supply stores immediately and from having a strong launch. We don’t believe any analysts have included adult-use revenue at all in 2022. The earlier start and having a larger number of retail stores will likely drive even more revenue for these operators in 2023 than previously anticipated.
When states legalize, they must take into account many considerations, including taxation, equity initiatives and how to treat incumbents in the medical market. It wasn’t that long ago that the idea was floated that the existing medical operators would be barred from participating in the adult-use market. When the details were finalized, however, the incumbents serving the New York medical cannabis market ended up in a very advantageous position. While future participants in the market will be limited to three adult-use stores the incumbents can have three adult-use as well as up to five medical-only stores. Only the existing 10 operators will be allowed to be vertically integrated. The regulatory structure in New York will likely lead to a lot of stores very quickly, which bodes well for the program’s future success.
We view this week’s news as very encouraging, as the launch in New York is likely to be much more robust than we have seen in other states that have legalized for adult-use. The state has addressed two challenges where other states have generally failed: create truly positive situations for social-equity entrepreneurs and hit the ground running on day one. In addition to benefiting the existing and new operators in the state, the New York launch of adult-use, like New Jersey’s, is likely to attract significant media attention.
After 13 extremely successful editions in Toronto, Chicago, Detroit, New York and Miami, the Benzinga Cannabis Capital Conference is going bigger than ever. Join us at the Fontainebleau Hotel in Miami Beach on April 20th and 21st.
Subscribers to the New Cannabis Ventures newsletter can use the code “NCVVIP” for 30% off your ticket
For the first time ever, browse the expo floor and discover to the brands that are shaping the cannabis industry. In addition, attendees will enjoy private meeting areas, comfortable seating and premium food options. Join live in Florida or attend from home. There’s no better place to connect with the people driving the global cannabis industry forward.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Acreage Holding Increases Q4 Revenue 21% Sequentially to $58.1 Million
- Ascend Wellness Q4 Revenue Declines 6% Sequentially to $88.5 Million
- Greenlane Sees Q4 Revenue at $55.5-56.5 Million
- Exclusive: Illinois Cannabis Sales Climb 29% in February
- IM Cannabis Projects 37% Sequential Gain in Q4 Revenue to C$20.3 Million
- Exclusive: Michigan Cannabis Sales Rebound in February
- Scotts Miracle-Gro Now Expects Hawthorne Sales to Decline 15-25% in Fiscal 2022
- TerrAscend Enters Michigan Cannabis Market With Completion of Gage Growth Acquisition
- Exclusive: This Edibles Company Is Quietly Expanding Its Footprint and Aiming for $200M in Revenue for 2022
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index and the Ancillary Cannabis Index.
View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Alan & Joel